Navigation Links
Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard

Treatment, According to a New Report from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

The new report entitled Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market finds that if an agent preventing recurrence of depressive mood episodes superior to that of sales-leading Wyeth's Effexor XR were to be launched, it would earn a 25 percent patient share, according to surveyed psychiatrists. The report also finds that although Effexor XR is the sales leader in the major depressive disorder drug market, the current and future Decision Resources proprietary clinical gold standard treatment for the indication is escitalopram (Lundbeck's Cipralex/Seroplex; Forest's Lexapro).

Although escitalopram's efficacy is not the highest in our study, the drug outscored any other current therapy in the area of safety. Experts we interviewed explain that because the drug is an active metabolite, lower doses can be used, an advantage that results in safety benefits.

"Based on available data and expert opinion, we do not expect any therapy under development to displace escitalopram as the clinical gold standard for major depressive disorder," said Carlos Dedesma, Ph.D., analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with escitalopram."

About the Report

Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
2. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
3. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
4. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
5. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
10. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
11. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
Post Your Comments:
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
(Date:11/30/2015)... 2015 Die MEDTEC Japan ... für Entwicklung und Herstellung medizinischer Geräte, ... 2016 in Tokyo ... Foto:- Foto: ... Logo: --> ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):